Last reviewed · How we verify
Gefarnyl (GEFARNATE)
Gefarnate works by inhibiting the enzyme involved in the production of leukotrienes, which are pro-inflammatory mediators.
Gefarnate, also known as GEFARNATE, is a small molecule drug in the gefarnate class. It is a medication that has been developed to treat certain conditions, although its exact target and approved indications are not specified. The commercial status of Gefarnate is unclear, with unknown patent status and generic manufacturers. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also not available. As a result, its safety profile and potential side effects are not well-documented.
At a glance
| Generic name | GEFARNATE |
|---|---|
| Drug class | gefarnate |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | discontinued |
Mechanism of action
Think of leukotrienes like messengers that tell your body to get inflamed. Gefarnate blocks these messengers from being made, which can help reduce inflammation and alleviate symptoms. This can be especially helpful for people with conditions like asthma or allergies.
Approved indications
Common side effects
Key clinical trials
- Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia (PHASE2,PHASE3)
- Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs (PHASE3)
- A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers (PHASE3)
- Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gefarnyl CI brief — competitive landscape report
- Gefarnyl updates RSS · CI watch RSS